![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Janssen’s Tremfya Approved for Active Psoriatic Arthritis
Janssen’s Tremfya Approved for Active Psoriatic Arthritis
July 15, 2020
The FDA has approved Janssen’s Tremfya (guselkumab) for treatment of adults with active psoriatic arthritis.
The approval was based on the results of two phase 3 clinical trials, in which a significant percentage of patients treated with Tremfaya experienced improvement compared to those given a placebo.
Tremfya is the first treatment to selectively inhibit interleukin (IL)-23, which is involved in inflammatory and immune responses associated with active psoriatic arthritis.
Upcoming Events
-
21Oct